These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

170 related articles for article (PubMed ID: 8930434)

  • 1. A pharmacoeconomic evaluation of intravenous fosphenytoin (Cerebyx) versus intravenous phenytoin (Dilantin) in hospital emergency departments.
    Marchetti A; Magar R; Fischer J; Sloan E; Fischer P
    Clin Ther; 1996; 18(5):953-66. PubMed ID: 8930434
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Cost-effectiveness of oral phenytoin, intravenous phenytoin, and intravenous fosphenytoin in the emergency department.
    Rudis MI; Touchette DR; Swadron SP; Chiu AP; Orlinsky M
    Ann Emerg Med; 2004 Mar; 43(3):386-97. PubMed ID: 14985668
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Phenytoin and fosphenytoin: a model of cost and clinical outcomes.
    Armstrong EP; Sauer KA; Downey MJ
    Pharmacotherapy; 1999 Jul; 19(7):844-53. PubMed ID: 10417033
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Fosphenytoin farewell?
    Horowitz BZ
    Ann Emerg Med; 2004 Mar; 43(3):398-400. PubMed ID: 14985669
    [No Abstract]   [Full Text] [Related]  

  • 5. Fosphenytoin. Pharmacoeconomic implications of therapy.
    Holliday SM; Benfield P; Plosker GL
    Pharmacoeconomics; 1998 Dec; 14(6):685-90. PubMed ID: 10346419
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Pharmacoeconomic considerations in treatment options for acute seizures.
    Graves N
    J Child Neurol; 1998 Oct; 13 Suppl 1():S27-9; discussion S30-2. PubMed ID: 9796750
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Inappropriate fosphenytoin use in the ED.
    Johnson J; Wrenn K
    Am J Emerg Med; 2001 Jul; 19(4):293-4. PubMed ID: 11447516
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Cost-minimization analysis of phenytoin and fosphenytoin in the emergency department.
    Touchette DR; Rhoney DH
    Pharmacotherapy; 2000 Aug; 20(8):908-16. PubMed ID: 10939551
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The safety, tolerability, and pharmacokinetics of fosphenytoin after intramuscular and intravenous administration in neurosurgery patients.
    Boucher BA; Feler CA; Dean JC; Michie DD; Tipton BK; Smith KR; Kramer RE; Young B; Parks BR; Kugler AR
    Pharmacotherapy; 1996; 16(4):638-45. PubMed ID: 8840370
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Evaluation of intramuscular fosphenytoin vs intravenous phenytoin loading in the ED.
    Aaronson PM; Belgado BS; Spillane JP; Kunisaki TA
    Am J Emerg Med; 2011 Nov; 29(9):983-8. PubMed ID: 20685063
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Randomized evaluation of adverse events and length-of-stay with routine emergency department use of phenytoin or fosphenytoin.
    Coplin WM; Rhoney DH; Rebuck JA; Clements EA; Cochran MS; O'Neil BJ
    Neurol Res; 2002 Dec; 24(8):842-8. PubMed ID: 12500711
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Fosphenytoin and phenytoin in patients with status epilepticus: improved tolerability versus increased costs.
    DeToledo JC; Ramsay RE
    Drug Saf; 2000 Jun; 22(6):459-66. PubMed ID: 10877039
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Fosphenytoin: clinical pharmacokinetics and comparative advantages in the acute treatment of seizures.
    Fischer JH; Patel TV; Fischer PA
    Clin Pharmacokinet; 2003; 42(1):33-58. PubMed ID: 12489978
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Fosphenytoin: a novel phenytoin prodrug.
    Boucher BA
    Pharmacotherapy; 1996; 16(5):777-91. PubMed ID: 8888074
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Intramuscular fosphenytoin (Cerebyx) in patients requiring a loading dose of phenytoin.
    Ramsay RE; Wilder BJ; Uthman BM; Garnett WR; Pellock JM; Barkley GL; Leppik IE; Knapp LE
    Epilepsy Res; 1997 Oct; 28(3):181-7. PubMed ID: 9332883
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Clinical experience with fosphenytoin in adults: pharmacokinetics, safety, and efficacy.
    Knapp LE; Kugler AR
    J Child Neurol; 1998 Oct; 13 Suppl 1():S15-8; discussion S30-2. PubMed ID: 9796747
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Fosphenytoin in infants.
    Takeoka M; Krishnamoorthy KS; Soman TB; Caviness VS
    J Child Neurol; 1998 Nov; 13(11):537-40. PubMed ID: 9853645
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Intramuscular use of fosphenytoin: an overview.
    Uthman BM; Wilder BJ; Ramsay RE
    Neurology; 1996 Jun; 46(6 Suppl 1):S24-8. PubMed ID: 8649611
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Comparison of Phenytoin and Fosphenytoin in Treatment of Active Seizures in the Emergency Department.
    Madhiyazhagan M; Roshan R; Dhanapal SG; Joseph JV; Ganesan P; Mathew V; A Kundavaram PP
    Neurol India; 2023; 71(3):447-452. PubMed ID: 37322738
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Cardiac arrest after fast intravenous infusion of phenytoin mistaken for fosphenytoin.
    DeToledo JC; Lowe MR; Rabinstein A; Villaviza N
    Epilepsia; 2001 Feb; 42(2):288. PubMed ID: 11240605
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 9.